STAT+: Warren, Grassley threaten to slap FDA with a 30-day deadline for OTC hearing aid rules
WASHINGTON – A bipartisan duo of senators is done waiting for the Food and Drug…
Category: STAT+
STAT+: Pharmalittle: Medicare finalizes plan for controversial Alzheimer’s drug; advocacy group faces controversy over CMS proposal
And so, another working week will soon draw to a close. Not a moment too…
STAT+: For patients, seeing the benefits of the new, fully sequenced genome could take years
Genomics has made significant inroads into mainstream medicine — DNA data are now routinely used…
STAT+: Biden’s new high-stakes research agency needs a home. For cities and states, the race for ARPA-H is on
WASHINGTON — The Biden administration’s new high-stakes research office has a name, an official place…
STAT+: Advocacy group’s advisory board members defect over Biogen Alzheimer’s drug
The furious debate over Biogen’s Alzheimer’s treatment has now sparked controversy over the Alliance for…
STAT+: Pharmalittle: Low-income Part D beneficiaries without subsidies often don’t fill scripts; Pfizer strikes a deal for RSV drugs
Hello, everyone, and how are you today? Gray skies are hovering over the chilly Pharmalot…
STAT+: A new crop of companies is reshaping the health data economy
It is one of health care’s most vexing quandaries: Patient data must be shared to…
STAT+: Many Medicare Part D beneficiaries don’t fill prescriptions for high-priced medicines
Medicare Part D beneficiaries who have low incomes and receive government subsidies were nearly twice…
STAT+: Pharmalittle: Most Americans would get a second booster shot; FDA pulls Glaxo Covid treatment
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it…
.jpg)
Opinion: STAT+: Reimagining R&D can cut drug development costs from billions to millions
In the course of our work advising biopharma companies, we are often asked how they…
STAT+: Virtual reality in medicine is garnering more investment. Will the health care system buy in?
As tech companies raise billions of venture capital dollars and completely rebrand to build out…
STAT+: STAT-Harris Poll: Most Americans would get a Covid-19 booster shot if recommended
As a Food and Drug Administration panel meets Wednesday to sort out the ongoing use…
STAT+: Colombian government faces calls to issue compulsory license for Pfizer’s Covid-19 pill
In the latest bid to expand access to the Pfizer Covid-19 pill, several advocacy groups…
STAT+: Troubles mount for Cassava Sciences, as patient enrollment lags for Alzheimer’s drug studies
Cassava Sciences conceded Tuesday that only a relative handful of patients with Alzheimer’s have been…
STAT+: Pharmalittle: Bluebird axes nearly one-third of its employees; Senate committee probes Merck’s tax practices
Hello, everyone, and how are you today? A cloudy cover greeted us this morning, but…
STAT+: Bluebird, troubled gene therapy maker, to lay off employees and reduce costs
Bluebird Bio is reducing expenses and laying off nearly a third of its employees to…
STAT+: Douglas Melton, noted stem cell researcher, leaves Harvard for Vertex to create diabetes treatments
Douglas Melton, one of the leading stem cell researchers in the world, is leaving Harvard…
STAT+: When a dire text message interrupted his talk, this doctor’s cancer research became painfully real
SAN DIEGO — If you’d seen him, you wouldn’t have known Scott Lippman was living…
STAT+: Biden administration funnels one of the largest-ever pay increases to Medicare Advantage insurers
The federal government is boosting the average payment to Medicare Advantage plans by 5% for…
STAT+: Hospital prices are soaring especially fast in Northern California. Here’s why
California’s lawmakers have spent decades crafting well-intentioned rules designed to keep the state’s healthcare prices…
STAT+: Medicare Part D and its beneficiaries could have saved millions if more biosimilars were accessible
Amid ongoing debate over biosimilar use in the United States, a new government analysis found…
STAT+: Pharmalittle: Novartis reorganizes and hopes to save $1 billion; industry-backed antibiotic fund makes first investments
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharma’s ambitious new antibiotic venture fund makes its first investments
One year after its splashy launch, the AMR Action Fund has made its first investments…
STAT+: The biotech scorecard for the second quarter: 21 stock-moving events to watch
Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the second…
STAT+: Pharmalittle: Califf admits Alzheimer’s drug controversy has hurt expert trust in FDA; House passes bill to lower insulin costs
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Mark Cuban’s company is building a ‘parallel supply chain’ for prescription drugs
Mark Cuban’s drug company started with an ambitious premise: to circumvent middlemen to offer cheaper…
.jpg)
STAT+: In the wake of Covid, a World Health Assembly proposal would bolster quality of clinical trials
Ahead of a World Health Assembly meeting in May, the United Kingdom is circulating a…
STAT+: The health tech tracker for the second quarter: the decisive industry deals and events to watch
As another Covid winter turns to spring, we’ll be watching to see whether 2022’s wave…
STAT+: Biden’s high-stakes biomedical science agency ARPA-H will be part of the NIH — but there’s a twist
WASHINGTON — President Biden’s “moonshot” biomedical research agency will be housed within the National Institutes…
STAT+: Pharmalittle: Advisory panel narrowly votes down ALS drug; Vertex looks to advance experimental pain drug
Good morning. Elizabeth Cooney here, borrowing the virtual Pharmalittle chair while Ed Silverman takes Manhattan…
STAT+: Vertex’s non-opioid painkiller meets goals in mid-stage studies
A novel pain drug from Vertex Pharmaceuticals met its goals in two mid-stage trials, the…
STAT+: 5 technology trends drawing investment as health care moves into the home
With Medicare expected to cover a projected 80 million people by 2030, entrepreneurs and investors…
With pharma still struggling in Alzheimer’s, health tech companies want a swing
In the wake of the first Alzheimer’s drug approval in nearly two decades, pharmaceutical companies…
STAT+: By narrow margin, FDA advisory panel concludes Amylyx ALS drug hasn’t proven effectiveness
For archived live coverage of the hearing of the FDA’s advisory panel, click here. By…
STAT+: Pharma companies face shareholder proposals to widen access to medicines, rework business plans
Over the next few weeks, several major pharmaceutical companies will face a fresh crop of…
STAT+: CVS, Teva, and Allergan reach massive deal with Florida over the opioid crisis
On the eve of a trial, the state of Florida has reached a massive settlement…
STAT+: Pharmalittle: Roche immunotherapy fails its first test; key U.S. senators move closer to bill to cap insulin prices
Hello, everyone, and how are you this fine, sunny morning? The middle of the week…
STAT+: Roche anti-TIGIT cancer immunotherapy fails in first late-stage clinical trial
Roche said Wednesday that an experimental cancer immunotherapy directed against a target called TIGIT failed…
STAT+: Tracking the FDA advisory panel on Amylyx Pharma’s ALS treatment
The Food and Drug Administration is convening a meeting of outside experts today to review…
STAT+: Pharma partnerships with digital therapeutics players to watch
With high-minded ambitions to revolutionize health care with the help of software, digital therapeutics companies…
STAT+: Hospitals, including some flush with cash, scramble to grab last scraps of federal Covid dollars
This month, executives at Freeman Health System, a three-hospital system based in Joplin, Mo., hired…
STAT+: Key senators eye new, more ambitious legislation to lower insulin prices
WASHINGTON — Key Senate lawmakers have begun writing a bipartisan bill that would cap the prices…
STAT+: HHS seeks to penalize another drugmaker amid legal clash over drug discount program
The U.S. Health and Resources Administration is seeking to penalize Boehringer Ingelheim for curtailing discounts…
STAT+: UnitedHealth’s deal with LHC highlights broader interest in home health industry
UnitedHealth Group’s proposed $5.4 billion buyout of home health and hospice provider LHC Group serves…
STAT+: Inflation caused ‘unprecedented’ drops in net pharmaceutical prices, analysis finds
Amid ongoing turmoil over the cost of prescription medicines, a new analysis finds that brand-name…
STAT+: Pharmalittle: Pfizer employees balk at returning overpayments; Biogen stops work on another ALS drug
Rise and shine, everyone, another busy day is on the way. This morning is getting…
STAT+: Lawmakers and a Pelosi aide turn lobbyist to push for new health agency’s independence
WASHINGTON — Health secretary Xavier Becerra is suddenly the target of a frenzied lobbying campaign…
STAT+: FDA review is critical of data on Amylyx ALS drug, but cites ‘regulatory flexibility’
Results from a single clinical trial of an experimental drug for ALS developed by Amylyx…
STAT+: Pharmalittle: Pharma showers cash on a rising U.S. Senate star; FDA restricts use of a Glaxo Covid treatment
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: She was told ‘girls don’t do that.’ Now Margaret-Mary Wilson is a top executive at UnitedHealth Group
Long before she became a top executive at UnitedHealth Group, back in her native Nigeria,…